# I'm a Pathologist. PCOS Is a Metabolic Disease. Ozempic and Mounjaro Just Proved It.

Canonical watch page: https://twitch-nude.com/watch/ozempic-and-mounjaro-exposed-a-90-year-mistake-about-pcos-pmos-v456427

Language: en

Published: 2026-08-22T00:00:15+00:00

Source creator: Dr. Amin Hedayat, MD

Duration: 1793 seconds

## Description

Women with PCOS are losing weight on Ozempic and Mounjaro. But that success can make one important part of the condition easier to miss.
 
In May 2026, an international consensus published in The Lancet renamed PCOS as PMOS (Polyendocrine Metabolic Ovarian Syndrome). I cover the 90-year history behind the old name, the insulin-androgen feedback loop that helps drive the condition, what semaglutide and tirzepatide improve, what they may not address, why endometrial protection can still matter, the truth about berberine, inositol, and peptides, and the four rules I'd give any woman with this condition.

The GLP-1 Method. Waitlist (Free):
???? https://getuninflamed.com

CHAPTERS
00:00 The 90-Year Medical Mistake
03:27 How PCOS Became an Ovarian Disease
06:09 The Two Hormone Loops Driving PMOS
08:22 What Your Skin Can Reveal
10:17 The Hidden Inflammation
11:45 What Weight-Loss Medications Get Right
13:56 The Anti-Inflammatory Effect Beyond Weight Loss
15:08 The Uncertain Effect on Testosterone
17:32 The Endometrial Risk Weight Loss Misses
20:31 Supplements and Peptide Marketing Claims
24:12 What the Evidence Still Can't Answer
25:25 Four Rules for Protecting Your Health
28:10 Treating the Whole Condition

ABOUT ME
I'm Dr. Amin Hedayat, MD, a triple board-certified pathologist and dermatopathologist with additional training in obesity medicine. I make evidence-based videos connecting pathology with metabolic health.
 
DISCLAIMER
This video is educational only, not medical advice, diagnosis, or treatment. Do not start, stop, or change any medication based on this video. Every medication decision belongs to you and your physician.

REFERENCES
1. Azziz R, Adashi EY. Am J Obstet Gynecol. 2016. https://doi.org/10.1016/j.ajog.2015.12.013
2. PMOS global consensus. The Lancet. 2026. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00717-8/fulltext
3. WHO PCOS fact sheet. 2026. https://www.who.int/news-room/fact-sheets/detail/polycystic-ovary-syndrome
4. Stener-Victorin E, et al. Nat Rev Dis Primers. 2024. https://doi.org/10.1038/s41572-024-00511-3
5. Acanthosis nigricans. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK431057/
6. Escobar-Morreale HF, et al. Fertil Steril. 2011. https://doi.org/10.1016/j.fertnstert.2010.11.036
7. Lin S, et al. Sci Rep. 2025. https://doi.org/10.1038/s41598-025-99622-4
8. Jastreboff AM, et al. SURMOUNT-1. N Engl J Med. 2022. https://doi.org/10.1056/NEJMoa2206038
9. Mosenzon O, et al. Cardiovasc Diabetol. 2022. https://doi.org/10.1186/s12933-022-01585-7
10. Morais BA, et al. J Diabetes Complications. 2024. https://doi.org/10.1016/j.jdiacomp.2024.108834
11. Barry JA, et al. Hum Reprod Update. 2014. https://doi.org/10.1093/humupd/dmu012
12. Khalenko VV, et al. Acta Biomed. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10210553/
13. Teede HJ, et al. 2023 International PCOS Guideline. https://www.monash.edu/__data/assets/pdf_file/0003/3371133/PCOS-Guideline-Summary-2023.pdf
14. PCOS update. Cleve Clin J Med. 2026. https://www.ccjm.org/content/93/3/176
15. Elahi Vahed I, et al. Int J Obes. 2026. https://doi.org/10.1038/s41366-025-01943-x
16. Wilding JPH, et al. STEP 1. N Engl J Med. 2021. https://doi.org/10.1056/NEJMoa2032183
17. Berberine marketplace potency testing, 33 products (commissioned by NOW; verified by Alkemist Labs). https://nutraceuticalbusinessreview.com/berberine-test-results-reveal-serious-quality-problems-from
18. NCCIH. Berberine and weight loss. https://www.nccih.nih.gov/health/berberine-and-weight-loss-what-you-need-to-know
19. Fitz V, et al. J Clin Endocrinol Metab. 2024. https://doi.org/10.1210/clinem/dgad762
20. FDA Compounding Advisory Committee, Jul 2026. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
21. EGRIFTA SV (tesamorelin) label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022505s012s013lbl.pdf
22. GEREF (sermorelin) withdrawal, Federal Register 2013. https://www.federalregister.gov/documents/2013/03/04/2013-04827/determination-that-geref-sermorelin-acetate-injection-05-milligrams-basevial-and-10-milligrams
23. Eli Lilly. Retatrutide TRIUMPH-2/3. 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional
24. FDA. Foundayo (orforglipron) approval, Apr 1, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program

#PCOS #Ozempic #Mounjaro #semaglutide #PMOS

This page provides video metadata, not a transcript. Watch the video on the canonical page.